CEL-SCI CORPORATION Increase (Decrease) in Operating Liabilities
CEL-SCI CORPORATION (CVM) reported Increase (Decrease) in Operating Liabilities of $900.00 thousand for the 12-month period ending 2020-09-30, per its 10-K filed 2020-12-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLiabilities · last filed 2020-12-31
- CEL-SCI CORPORATION increase (decrease) in operating liabilities for the quarter ending 2020-09-30 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in operating liabilities for fiscal 2020 was $900.00K.
| Period end | Increase (Decrease) in Operating Liabilities 3 month | Increase (Decrease) in Operating Liabilities 9 month | Increase (Decrease) in Operating Liabilities 12 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2020-12-29 | $900.00K 10-K · filed 2020-12-29 | |
| 2020-06-30 | $900.00K 10-Q/A · filed 2020-12-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |